In a regulatory filing, SPARC said that its partner, Sun Pharmaceutical Industries (SPIL), reported top-line results from ...

Sun Pharma Advanced Research Company (SPARC) psoriasis drug, Vibozilimod (SCD-044), failed to meet primary endpoints in Phase ...

SPARC said that the psoriasis and atopic dermatitis drug, SCD-044 or Vibozilimod, had been licenced to its parent company, ...

Sun Pharma Advanced Research share price tanked 20 per centa after Vibozilimod (SCD-044) studies failed to meet the primary ...

Sun Pharma's shares experienced a 0.47 per cent decline, trading at Rs 1,659.80, alongside the sharper fall in SPARC shares ...

The shares of Sun Pharma Advanced Research Company (SPARC) fell over 18 per cent on Wednesday, on BSE, on the announcement ...

Shares of Sun Pharma Advanced Research Company (SPARC) shares crashed significantly on Wednesday after the company announced ...

Shares of Sun Pharma Advanced Research Company (SPARC), the research division of India’s largest pharmaceutical firm Sun Pharma, fell 19 per cent to Rs 158 each after unsatisfactory Phase 2 trial ...

SPARC and its partner Sun Pharma said they will "evaluate the appropriate next steps", but the setback sent its shares tumbling nearly 18% on the BSE on Wednesday.

Sun Pharma Advanced Research Company (SPARC) shares plummeted nearly 20% after its psoriasis drug, SCD-044, failed to meet primary endpoints in Phase 2 trials.